{"filing":{"accession_number":"0001193125-26-427890","cik":"0001107421","ticker":"TCRT","company_name":"Alaunos Therapeutics, Inc.","form":"8-K","filing_date":"2026-10-21","report_date":"2026-10-21","primary_document":"tcrt-20261021.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1107421/000119312526427890/tcrt-20261021.htm"},"events":[{"id":36811,"run_id":33937,"accession_number":"0001193125-26-427890","anchor_item_number":"3.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"summary":"The filing discloses Alaunos' receipt of a Nasdaq deficiency notice on April 9, 2026 for failure to maintain the $2.5 million stockholders' equity requirement, followed by a delisting notice on October 5, 2026 due to continued non-compliance. Although the Company claims to have regained compliance through the October 14, 2026 financing ($350 million in proceeds), the disclosure explicitly states that Nasdaq will continue monitoring compliance and \"if at the time of the filing of the Company's Annual Report on Form 10-K for the fiscal year ending December 31, 2026 the Company does not evidence compliance, the Company may be subject to delisting.\" This is a classic delisting-risk disclosure under Item 3.01, with material uncertainty about sustained compliance.","company_name":"Alaunos Therapeutics, Inc.","ticker":"TCRT","filing_date":"2026-10-21","form":"8-K","submitted_at":null,"items":[{"id":41348,"accession_number":"0001193125-26-427890","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"The filing discloses Alaunos' receipt of a Nasdaq deficiency notice on April 9, 2026 for failure to maintain the $2.5 million stockholders' equity requirement, followed by a delisting notice on October 5, 2026 due to continued non-compliance. Although the Company claims to have regained compliance through the October 14, 2026 financing ($350 million in proceeds), the disclosure explicitly states that Nasdaq will continue monitoring compliance and \"if at the time of the filing of the Company's Annual Report on Form 10-K for the fiscal year ending December 31, 2026 the Company does not evidence compliance, the Company may be subject to delisting.\" This is a classic delisting-risk disclosure under Item 3.01, with material uncertainty about sustained compliance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-21T20:43:13.597330+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":41348,"accession_number":"0001193125-26-427890","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"The filing discloses Alaunos' receipt of a Nasdaq deficiency notice on April 9, 2026 for failure to maintain the $2.5 million stockholders' equity requirement, followed by a delisting notice on October 5, 2026 due to continued non-compliance. Although the Company claims to have regained compliance through the October 14, 2026 financing ($350 million in proceeds), the disclosure explicitly states that Nasdaq will continue monitoring compliance and \"if at the time of the filing of the Company's Annual Report on Form 10-K for the fiscal year ending December 31, 2026 the Company does not evidence compliance, the Company may be subject to delisting.\" This is a classic delisting-risk disclosure under Item 3.01, with material uncertainty about sustained compliance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-21T20:43:13.597330+00:00","company_name":"Alaunos Therapeutics, Inc.","ticker":"TCRT","filing_date":"2026-10-21"}]}